People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

If you can’t or don’t want to take Ozempic, your healthcare professional may recommend a different medication. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist medication that ...

GLP-1 drugs such ... be offering single-dose vials of Zepbound to patients with obesity. (It comes at a lower price point than the medication when delivered in an injection pen.) ...

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist, or GLP-1 RA, known as semaglutide. The latest FDA approval makes the medication the first GLP-1 treatment option for people with type ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of ...